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Summary
Objective:	 Hyperinsulinaemic	 hypoglycaemia	 (HH)	 can	 occur	 in	 isolation	 or	more	
rarely	feature	as	part	of	a	syndrome.	Screening	for	mutations	in	the	“syndromic”	HH	
genes	is	guided	by	phenotype	with	genetic	testing	used	to	confirm	the	clinical	diag-
nosis.	As	HH	can	be	the	presenting	feature	of	a	syndrome,	it	is	possible	that	muta-
tions	will	be	missed	as	these	genes	are	not	routinely	screened	in	all	newly	diagnosed	
individuals.	We	investigated	the	frequency	of	pathogenic	variants	in	syndromic	genes	
in	infants	with	HH	who	had	not	been	clinically	diagnosed	with	a	syndromic	disorder	
at	referral	for	genetic	testing.
Design:	We	used	genome	sequencing	data	to	assess	the	prevalence	of	mutations	in	
syndromic	HH	 genes	 in	 an	 international	 cohort	 of	 patients	with	HH	 of	 unknown	
	genetic	cause.
Patients:	We	undertook	genome	sequencing	in	82	infants	with	HH	without	a	clinical	
diagnosis	of	a	known	syndrome	at	referral	for	genetic	testing.
Measurements:	Within	this	cohort,	we	searched	for	the	genetic	aetiologies	causing	
20	different	syndromes	where	HH	had	been	reported	as	a	feature.
Results:	We	identified	a	pathogenic	KMT2D	variant	in	a	patient	with	HH	diagnosed	at	
birth,	confirming	a	genetic	diagnosis	of	Kabuki	syndrome.	Clinical	data	received	fol-
lowing	the	identification	of	the	mutation	highlighted	additional	features	consistent	
with	the	genetic	diagnosis.	Pathogenic	variants	were	not	identified	in	the	remainder	
of	the	cohort.
Conclusions:	Pathogenic	variants	in	the	syndromic	HH	genes	are	rare;	thus,	routine	
testing	of	these	genes	by	molecular	genetics	laboratories	is	unlikely	to	be	justified	in	
patients	without	syndromic	phenotypes.
K E Y W O R D S
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1  | INTRODUC TION
Congenital	hyperinsulinaemic	hypoglycaemia	(HH)	is	a	disorder	where	
episodes	of	hypoglycaemia	are	caused	by	unregulated	insulin	secre-
tion	despite	low	blood	glucose	levels.	Prompt	treatment	is	crucial	in	
order	 to	 avoid	 serious	 lifelong	 complications	 such	 as	 seizures	 and	
permanent	brain	injury.1	Genetic	testing	is	important	for	the	clinical	
management	of	this	condition	as	 identifying	the	underlying	genetic	
aetiology	will	inform	on	the	pancreatic	histology	which,	for	patients	
who	are	unresponsive	to	medical	 treatment,	will	help	to	determine	
whether	a	lesionectomy	or	a	near‐total	pancreatectomy	is	required.2
HH	is	most	commonly	the	result	of	a	monogenic	aetiology	with	
mutations	in	at	least	eight	genes	reported	to	cause	isolated	disease.3 
Routine	screening	of	these	genes	using	a	combination	of	rapid	Sanger	
sequencing	and	targeted	next‐generation	sequencing	identifies	a	mu-
tation	in	approximately	40%‐50%	of	cases	with	persistent	HH.3	This	
suggests	that	further	genetic	aetiologies	remain	to	be	discovered.
HH	has	also	been	reported	as	a	feature	in	at	least	20	different	rare	
genetic	syndromes.1	The	most	common	is	Beckwith‐Wiedemann	syn-
drome	where	HH	occurs	in	approximately	50%	of	cases.4	More	rarely,	
HH	has	been	described	 in	 individuals	with	other	overgrowth	disor-
ders	including	Sotos	syndrome5	and	growth	delay	syndromes	such	as	
Kabuki.6	HH	has	also	been	reported	in	some	cases	with	congenital	dis-
orders	of	glycosylation	and	chromosome	abnormalities	such	as	Turner	
syndrome	and	Patau	syndrome.7-10	For	patients	with	syndromic	HH,	
an	early	genetic	diagnosis	is	important	as	this	will	guide	medical	man-
agement	and	provide	information	on	prognosis	and	recurrence	risk.
Screening	 of	 the	 syndromic	 genes	 is	 not	 routinely	 performed	
as	part	of	the	genetic	testing	strategy	for	individuals	with	HH.	The	
targeted	 analysis	 of	 a	 gene	 is	 usually	 only	 performed	when	 there	
is	 a	 clinical	 suspicion	 of	 a	 specific	 syndrome	 in	 an	 individual	 and	
therefore	 acts	 to	 confirm	 the	 clinical	 diagnosis.11	 Consequently,	
the	prevalence	of	mutations	in	these	genes	in	HH	is	not	known.	As	
many	patients	are	referred	for	genetic	testing	at	diagnosis	of	HH,	it	is	 
	possible	that	some	individuals	with	a	mutation	in	a	syndromic	gene	
will	not	have	developed	additional	extra‐pancreatic	features	at	the	
time	of	referral	for	genetic	testing.	These	patients	may	therefore	not	
receive	the	most	appropriate	genetic	testing.
In	order	to	assess	the	frequency	of	mutations	in	the	known	syn-
dromic	genes	in	individuals	with	HH	of	unknown	genetic	cause,	we	
performed	 a	 comprehensive	 analysis	 of	 genome	 sequencing	 data	
from	 82	 affected	 infants.	 Screening	 patients	 for	 mutations	 in	 the	
“syndromic”	HH	genes	irrespective	of	clinical	features	has	the	advan-
tage	that	a	genetic	diagnosis	can	precede	development	of	clinical	fea-
tures	and	guide	clinical	management,	rather	than	being	confirmatory.
2  | MATERIAL S AND METHODS
2.1 | Patient details
82	infants	with	HH	diagnosed	within	the	first	12	months	of	life	were	
referred	 for	genetic	 testing	 to	 the	Molecular	Genetics	Laboratory	
at	the	Royal	Devon	and	Exeter	NHS	Foundation	Trust.	All	patients	
in	 the	cohort	had	 received	a	biochemical	diagnosis	of	HH	 in	 their	
local	centre.	All	patients	had	a	blood	glucose	of	<2.8	mmol/L	(me-
dian	1.9	mmol/L)	with	a	concomitant	insulin	of	>15	pmol/L	(median	
96	pmol/L)	 and/or	 a	 c‐peptide	of	>300	pmol/L	 (see	Table	1).	 In	 all	
cases,	 the	HH	had	persisted	 for	greater	 than	6	months	or	had	 re-
quired	pancreatic	resection	following	a	poor	response	to	treatment.	
In	15	patients,	extra‐pancreatic	features	were	present	at	the	time	of	
referral	for	genetic	testing.	None	of	these	patients	had	received	a	
clinical	diagnosis	consistent	with	a	known	syndromic	form	of	HH	at	
the	time	of	study.	Mutations	in	the	ABCC8, KCNJ11, HADH, HNF4A, 
HNF1A, GLUD1, GCK, and SLC16A1	genes	had	been	excluded	in	all	
patients	 using	 targeted	 next‐generation	 sequencing.11 The cod-
ing	 regions	of	 the	HH	candidate	genes,	UCP2 and HK1,	were	also	
screened	 but	 no	 likely	 pathogenic	 variants	were	 identified	 in	 the	
cohort.12‐14 
The	 study	was	 approved	 by	 the	North	Wales	 Research	 Ethics	
Committee.	Consent	was	obtained	from	each	patient	after	 full	ex-
planation	of	the	purpose	and	nature	of	all	procedures	used.
2.2 | Gene panel and variant calling
We	utilized	the	Phenomizer	browser	to	identify	disease	entries	an-
notated	for	hyperinsulinaemic	hypoglycaemia	(HPO	id:	0000825).15 
A	survey	of	 the	 literature	was	also	undertaken	 to	 identify	 further	
genes	in	which	mutations	have	been	reported	to	cause	HH	as	part	
of	a	syndrome.
Whole‐genome	 sequencing	 was	 performed	 on	 DNA	 extracted	
from	 peripheral	 blood	 leucocytes	 of	 the	 82	 probands.	 All	 samples	
were	sequenced	on	an	Illumina	HiSeq	2500	or	Illumina	X10	(Illumina,	
San	Diego,	California,	USA)	with	a	mean	read	depth	of	33.25	(SD	4.25).	
The	sequencing	data	were	analysed	using	an	approach	based	on	the	
GATK	best	practice	guidelines.16	This	 involved	aligning	the	reads	to	
the	hg19/GRCh37	human	reference	genome	with	BWA	mem,	apply-
ing	Picard	for	duplicates	removal,	and	GATK	IndelRealigner	for	local	
realignment	 and	 running	 the	base	quality	 score	 realignment.	GATK	
TA B L E  1  Clinical	characteristics	of	the	82	patients	included	in	
this	study.	All	patients	had	received	a	clinical	diagnosis	of	HH	from	
their	referring	clinician,	with	biochemical	testing	undertaken	in	
their	local	laboratories.	When	applicable,	median	values	are	given	
with	the	range.
Reported	consanguineous 18%
Sex	(%	male) 48%
Birth	weight	kg	(gestation) 3.5	(39	wk)	[2.0‐5.2	
(35‐41	wk)]
Current	age	(y) 6.5	[1‐35]
Age	at	diagnosis	of	HH	(wk) 4	[0‐48]
Blood	glucose	at	diagnosis	(mmol/L) 1.9	[<1‐2.8]
Insulin	at	time	of	hypoglycaemia	(pmol/L) 96	[15‐365]
C‐peptide	at	diagnosis	(pmol/L) 775	[150‐2400]
Extra‐pancreatic	features n = 15
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TA B L E  2  Syndromes	in	which	hyperinsulinaemic	hypoglycaemia	(HH)	has	been	reported	as	a	feature.	The	18	genes	in	which	mutations	
have	been	reported	to	cause	syndromic	HH	plus	the	three	genomic	regions	known	to	be	affected	by	copy	number	variants	(CNVs)	or	
uniparental	isodisomy	(UPD)	are	provided.
Syndrome OMIM Gene(s) Inheritance References HH clinical featuresa
Adenosine	kinase	
deficiency
ADK Recessive Staufner	et	al23 Neonatal	onset.	Recurrent.	
Diazoxide	responsive
Congenital	disorders	of	
glycosylation	(type	1d)
ALG3 Recessive Sun	et	al7 Neonatal	onset
Timothy CACNA1C Dominant Splawski	et	al24 Childhood	onset.	
Recurrent
CACNA1D CACNA1D Dominant Flanagan	et	al25 Onset	from	birth.	
Persistent	and	transient	
reported.	Diazoxide	
responsive
Beckwith‐Wiedemann CDKN1C,	UPD	or	CNVs	at	
11p15
Dominant Munns	and	Batch4 Onset	in	neonatal	period.	
Transient.	Diazoxide	
responsive
Perlman DIS3L2 Recessive Henneveld	et	al26 Onset	from	birth
Tyrosinaemia	type	I FAH Recessive Baumann	et	al27 Neonatal	onset.	Transient.	
Diazoxide	responsive
Simpson‐Golabi‐Behmel GPC3 X‐linked	recessive Terespolsky	et	al28 Neonatal	onset
Costello HRAS Dominant Sheffield	et	al29 Onset	from	birth.	
Transient
Insulin	resistance	
syndrome	
(leprechaunism)
INSR Dominant Hojlund	et	al30 Onset	3	to	30	years	of	age.	
Postprandial	HH.	
Octreotide	responsive
Kabuki KMT2D, KDM6A Dominant Gole	et	al6 Onset	from	birth.	
Persistent.	Diazoxide	
responsive
Congenital	disorder	of	
glycosylation	(type	1b)
MPI Recessive Deeb and 
Amoodi31
Neonatal	onset.	
Persistent.	Diazoxide	
responsive
Sotos NSD1 Dominant Baujat	et	al5 Neonatal	onset.	
Persistent.	Diazoxide	
responsive
Congenital	disorder	of	
glycosylation	(type	1t)
PGM1 Recessive Tegtmeyer	et	al8 Childhood	onset.	
Recurrent
Central	hypoventilation	
syndrome
PHOX2B Dominant Hennewig	et	al32 Neonatal	onset.	Recurrent.	
Diazoxide	responsive
Congenital	disorder	of	
glycosylation	(type	1a)
PMM2 Recessive Bohles	et	al33 Neonatal	onset.	
Persistent.	Diazoxide	
responsive
Polycystic	Kidney	
Disease	with	HH
PMM2 Recessive Cabezas	et	al9 Neonatal/childhood	onset.	
Persistent.	Diazoxide	
responsive
TRMT10A TRMT10A Recessive Gillis	et	al34 Childhood	onset.	
Persistent.	Diazoxide	
responsive
Patau	syndrome Trisomy	13  De novo Smith	and	Giacoia35 Onset	from	birth.	
Transient
Turner X	Chromosome	deletions  De novo Alkhayyat	et	al10 Neonatal	onset.	
Persistent.	Diazoxide	
responsive
aFeatures	of	HH	as	reported	in	cases	from	the	published	literature.	
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haplotypeCaller	was	used	to	identify	variants,	which	were	annotated	
using	 Alamut	 Batch	 version	 1.8	 (Interactive	 Biosoftware,	 Rouen,	
France),	and	variants	which	failed	the	QD2	VCF	filter	or	had	<5	reads	
supporting	the	variant	allele	were	excluded.	Variants	that	passed	fil-
tering	were	confirmed	by	Sanger	sequencing	and	tested	in	the	parents	
(details	 of	 primer	 sequences	 are	 available	 on	 request).	 CNVs	were	
called	by	SavvyCNV,	which	uses	 read	depth	 to	 judge	copy	number	
states.17	Uniparental	isodisomy	was	detected	using	a	hidden	Markov	
model	 to	 detect	 regions	with	 a	 significant	 number	 of	 variants	 that	
were	opposite	homozygous	between	the	proband	and	one	parent.
3  | RESULTS
We	 identified	 20	 genetic	 syndromes	 in	 which	 HH	 has	 been	 re-
ported	 as	 a	 feature	 (Table	2).	 In	 82	 patients,	 we	 screened	 the	
coding	regions	and	intron/exon	boundaries	of	the	18	genes	associ-
ated	with	these	syndromes.	We	also	searched	for	copy	number	var-
iations	 (CNVs)	 and	evidence	of	uniparental	 isodisomy	at	genomic	
regions	 associated	with	 Beckwith‐Wiedemann,	 Patau	 and	 Turner	
syndromes.
We	identified	70	nonsynonymous	 (nonsense,	 frameshift,	splice	
site,	missense)	variants	 in	the	18	genes.	As	the	incidence	of	HH	in	
outbred	populations	is	estimated	to	be	between	1	in	27	000	and	1	in	
50	000,18	we	excluded	all	variants	in	dominant	genes	that	were	pres-
ent	in	gnomAD	controls19	at	a	frequency	greater	than	1	in	27	000.	In	
addition,	we	excluded	variants	that	did	not	fit	the	known	inheritance	
pattern	of	the	syndrome:	excluding	single	heterozygous	variants	in	
recessive	 genes	 and	 variants	 inherited	 from	 an	 unaffected	 parent	
in	dominant	genes.	This	left	one	de novo	variant	in	the	KMT2D	gene	
where	dominantly	inherited	loss‐of‐function	mutations	are	reported	
to	cause	Kabuki	syndrome.6 
F I G U R E  1     KMT2D	variant	hg19/GRCh37:g.49420017_49420018del/NM_003482:c.15731_15732del/p.Lys5244Serfs*13.	Visualized	
in	integrative	genomics	viewer	(IGV).	It	shows	the	sequencing	reads.	(horizontal	grey	bars)	mapping	to	exon	48	of	the	 KMT2D	gene	located	
at	genomic	position	49,420,017	on	chromosome	12.	The	reference	nucleotide	sequence	and	the	amino	acid	translation	are	provided	under	
the	sequencing	reads.	The	heterozygous	deletion	of	TT	is	illustrated	by	‐2‐	and	is	present	in	15	of	the	25	sequencing	reads	present	at	this	
position.	The	deletion	causes	a	frameshift.
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CNVs	were	not	detected	at	any	of	the	regions	analysed,	and	anal-
ysis	of	single	polymorphisms	excluded	uniparental	isodisomy	at	the	
Beckwith‐Wiedemann	syndrome	locus	at	chromosome	11p15.5.	All	
patients	had	normal	dosage	of	chromosome	13,	and	all	females	had	
a	 46XX	 karyotype,	 which	 excluded	 Patau	 and	 Turner	 syndromes,	
respectively.
The	 heterozygous	 frameshift	 variant	 in	 the	 KMT2D	 gene	
p.(Lys5244Serfs*13),	 (c.15731_15732del)	 and	 (NM_003482.3)	
(Figure	1)	 had	 arisen	de novo	 in	 the	proband	and	was	 classified	 as	
“pathogenic”	according	to	the	American	College	of	Medical	Genetic	
guidelines.20	The	 female	patient	was	of	Sarawakian	ethnicity	born	
in	Malaysia	to	nonconsanguineous	parents	at	38	weeks	of	gestation	
with	a	birthweight	of	3.36	kg.	During	the	pregnancy,	her	mother	was	
diagnosed	with	gestational	diabetes	that	was	controlled	by	diet	and	
the	pregnancy	was	complicated	by	polyhydramnios.	Hypoglycaemia	
was	diagnosed	in	the	proband	at	birth	(2.0	mmol/L),	which	required	
intermittent	intravenous	dextrose	for	recurrent	symptomatic	hypo-
glycaemia	until	day	30	of	life.	Diazoxide	treatment	(5	mg/kg/d)	and	
hydrochlorothiazide	treatment	(1.5	mg/kg/twice	daily)	were	started	
at	30	days,	which	 resulted	 in	euglycaemia.	Hyperinsulinism	as	 the	
cause	of	hypoglycaemia	was	confirmed	biochemically.	The	patient	
required	continuous	diazoxide	treatment	and	a	nasogastric	tube	for	
feeding.	 At	 the	 age	 of	 6	months,	 the	 patient	was	 referred	 for	 ge-
netic	testing	of	the	genes	causing	isolated	HH.	At	referral,	the	only	
extra‐pancreatic	 feature	 reported	 to	 the	 genetics	 laboratory	 was	
gastro‐oesophageal	reflux.	At	follow‐up	subsequent	to	the	genetic	
diagnosis,	 clinical	 features	 consistent	 with	 a	 diagnosis	 of	 Kabuki	
syndrome	were	 reported.	At	 the	age	of	5	months,	her	weight	was	
6.06	kg	 (10th‐50th	 centile),	 height	was	 60	cm	 (<10th	 centile),	 and	
head	circumference	was	38.5	cm	(<10th	centile).	She	had	soft	facial	
dysmorphism,	 hypotonia	 and	 laryngomalacia	 with	 inspiratory	 stri-
dor.	Her	gross	and	 fine	motor	development	was	delayed.	She	also	
had	 a	 resolved	 small	 muscular	 ventricular	 septal	 defect	 and	 con-
genital	small	right	kidney	with	normal	left	kidney.	She	had	recurrent	
pneumonia	and	died	before	reaching	1	year	of	age.
4  | DISCUSSION
We	screened	for	genetic	aetiologies	where	HH	has	been	reported	
to	 feature	as	part	of	 a	 complex	 syndrome	 in	82	patients	with	HH	
of	 unknown	 cause.	 We	 identified	 one	 patient	 with	 a	 pathogenic	
variant	in	KMT2D	that	confirmed	a	diagnosis	of	Kabuki	syndrome.6 
At	referral,	 the	patient	was	reported	to	the	genetics	 laboratory	as	
having	persistent	HH	and	gastro‐oesophageal	 reflux.	At	 follow‐up	
subsequent	 to	 the	 genetic	 diagnosis,	 clinical	 features	 consistent	
with	a	diagnosis	of	Kabuki	syndrome	were	reported.	These	included	
a	 structural	heart	defect	with	growth	and	developmental	delay.	 It	
is	possible	that	if	the	patient	had	been	referred	to	a	specialist	clini-
cal	 geneticist,	 a	 clinical	diagnosis	of	Kabuki	 syndrome	would	have	
been	made.	As	 the	patient	died	before	 the	 age	of	1	year,	 it	 is	 not	
possible	 to	 ascertain	whether	 they	would	 have	developed	 further	
features	of	this	syndrome.	Recently,	Yap	et	al21	described	a	cohort	
of	10	patients	with	pathogenic	 variants	 in	KDM6A	who	presented	
with	HH	before	receiving	a	diagnosis	of	Kabuki	syndrome	later	in	life	
suggesting	that	HH	may	be	a	more	common	presenting	feature	than	
previously	recognized.	Their	screening	of	an	additional	100	isolated	
HH	patients	identified	one	further	patient	(who	was	retrospectively	
recognized	to	have	the	classic	syndromic	phenotype),	which	is	a	simi-
lar	frequency	to	our	study.
Mutations	 in	 the	 “syndromic”	 HH	 genes	 were	 not	 identified	
in	the	majority	of	our	cohort	 (81/82	patients).	Our	patients	were	
selected	due	to	the	presence	of	persistent	HH	rather	than	a	syn-
dromic	 phenotype.	Our	 low	pickup	 rate	 suggests	 that	mutations	
in	 these	 genes	 are	 rare	 in	 patients	 presenting	with	 isolated	HH.	
It	 is	 likely	 that	 for	 the	majority	of	 cases	with	 syndromic	disease,	
additional	 features	 are	 evident	 from	 birth	 allowing	 for	 a	 clinical	
diagnosis	 followed	 by	 confirmatory	 genetic	 testing.	 This	 would	
consequently	 reduce	 the	 prevalence	 of	 cases	 within	 our	 cohort	
as	 the	majority	 of	 patients	 are	 referred	 for	 routine	 screening	 of	
the	8	known	 isolated	HH	genes.	Heterozygous	variants	 in	genes	
that	cause	a	dominant	disease	were	excluded	 if	 they	were	 inher-
ited	from	an	unaffected	parent;	however,	it	is	possible	that	these	
could	be	pathogenic	but	displaying	 incomplete	penetrance	 in	the	
parents.	We	can	also	not	rule	out	the	possibility	that	some	patients	
have	mutations	in	other	genes	known	to	cause	multisystem	disease	
which	was	not	screened	 in	this	study	as	HH	has	not	been	recog-
nized	as	a	common	feature.	Furthermore,	 it	 is	possible	that	some	
patients	with	Beckwith‐Wiedemann	syndrome	have	a	methylation	
defect	in	the	absence	of	a	structural	abnormality	that	was	not	de-
tected	by	our	analysis.
The	 finding	 that	 the	patient	with	Kabuki	 syndrome	had	HH	as	
the	presenting	feature	highlights	the	potential	benefit	of	screening	
for	 the	 syndromic	 genes	 in	 individuals	 newly	 diagnosed	with	HH.	
Identifying	the	underlying	genetic	aetiology	 is	 important	for	these	
patients	as	it	will	inform	on	prognosis	which	will	allow	for	better	clin-
ical	management.	A	genetic	diagnosis	also	provides	important	infor-
mation	on	recurrence	risk.
We	found	that	mutations	causing	these	20	syndromes	are	rare.	
The	recent	adoption	of	targeted	next‐generation	sequencing	by	mo-
lecular	genetics	 laboratories	makes	screening	of	multiple	genes	 for	
conditions	such	as	HH	feasible.	An	early	and	accurate	genetic	diag-
nosis	 of	 a	 syndrome	has	 benefits	 for	 patient	 care.	However,	 there	
are	some	disadvantages	of	this	approach	in	terms	of	the	difficulties	
with	variant	 interpretation	 in	the	absence	of	additional	clinical	 fea-
tures	and	the	extra	time	required	for	the	analysis	of	the	genetic	data.	
Thus,	routine	testing	of	this	panel	of	genes	may	not	be	justified	for	
patients	without	 syndromic	 features	as	we	have	shown	that	muta-
tions	 in	these	genes	are	rare	 in	such	a	cohort.	 It	 is	anticipated	that	
variant	interpretation	will	become	easier	through	data	sharing	initia-
tives	such	as	ClinVar,22	and	as	the	number	of	publically	available	con-
trol	data	sets	increase,	more	variants	can	be	excluded	by	frequency.19 
This	may	make	testing	of	these	genes	 in	all	patients	with	HH	more	
feasible	in	future.
Screening	large	cohorts	for	mutations	in	these	genes	will	provide	
further	information	on	the	prevalence	of	mutations	in	HH,	which	will	
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help	to	guide	future	genetic	screening	strategies	for	this	condition	
and	may	also	identify	individuals	with	“nonclassical”	features,	which	
would	expand	the	phenotype	associated	with	these	syndromes.
In	conclusion,	while	the	clinical	 impact	of	finding	a	mutation	in	
a	syndromic	gene	is	high	as	it	can	inform	clinical	management,	mu-
tations	 in	 the	syndromic	HH	genes	are	 rare	 in	 individuals	 referred	
for	 routine	 testing	 for	HH.	Given	 the	 time‐consuming	nature	of	 a	
comprehensive	screen,	routine	testing	of	these	genes	by	molecular	
genetics	 laboratories	 is	 unlikely	 to	be	 justified	 in	patients	without	
syndromic	phenotypes.
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